The latest food and beverage industry news and trend analysis

Superbrewed Food has announced a major manufacturing and financial milestone, confirming that global ingredient supplier Döhler has commenced commercial production of its SB1™ Postbiotic Cultured Protein. The development marks the food-tech industry's first commercial-scale manufacturing of a postbiotic protein that holds an FDA-reviewed GRAS ('no questions' letter) status.

To cement the partnership, Döhler Ventures has also made a strategic investment in Superbrewed, signalling long-term institutional backing for fermentation-enabled nutrition and the global scaling of the SB1™ ingredient.

Scaling Production for the US Market

The transition from development to commercial-phase production is currently being executed at one of Döhler’s European manufacturing facilities, leveraging the conglomerate's massive global infrastructure and quality control systems.

According to Superbrewed, the initial commercial volumes produced at the European site are already shipping into the United States, specifically targeting premium sports and lifestyle nutrition applications.

Bryan Tracy, CEO of Superbrewed Food, highlighted the critical nature of the manufacturing partnership: "Establishing commercial production with Döhler is a defining step for Superbrewed. Döhler's global manufacturing platform and commercialisation capabilities position SB1™ to scale efficiently and meet accelerating demand for high-quality protein."

Formulation Specs: Nutrient Density and Clean Label

SB1™ is an anaerobic fermentation-derived, whole-food protein ingredient. Unlike isolated plant or dairy proteins, it delivers a highly concentrated nutritional profile that includes meaningful levels of naturally occurring B-vitamins and essential minerals. This native nutrient density allows food and beverage manufacturers to make distinct structure/function claims on finished products.

Key Ingredient Attributes:

• Dietary Profile: Vegan, Non-GMO, and entirely Allergen-Free.

• Functionality: Supports clean-label formulations across both solid food and liquid nutrition applications.

• Sustainability: The platform utilises an efficient bioconversion process that transforms sugar supply into high-value protein biomass.

Formulating for the GLP-1 Consumer

The commercialisation of SB1™ arrives at a critical juncture for the CPG sector. The widespread adoption of GLP-1 weight-loss medications has catalysed a structural shift in dietary demand, pushing consumers toward smaller, highly nutrient-dense portions that prioritize protein and minimise sugar.

Superbrewed's platform directly addresses this shift, offering formulators a premium ingredient that goes beyond simple macronutrient targets to deliver holistic nutritional value.

Rodrigo Hortega de Velasco, Managing Partner at Döhler Ventures, commented on the strategic fit: "Superbrewed's SB1™ represents a differentiated innovation in the evolving protein landscape. Through commercial manufacturing and strategic investment, we are committed to supporting SB1™ as it scales globally."

The companies have already outlined a long-term roadmap, confirming plans to further expand production capacity and advance broader commercialisation initiatives together in 2027.